Key Takeaways
- Recovery taking hold, margin rebound underway: Revenue grew 11% YoY and EBITDA surged 94% QoQ as export demand revived and capacity utilization tightened; management sees clear visibility for sequential margin expansion through at least December.
- SDA volumes strong, value lags: Management is "absolutely sure" of hitting volume commitments but concedes it will miss value targets because raw material costs have collapsed, dragging pricing down.
- The pipeline is converting: Two large agro intermediates, a second electrolyte salt, and a photo-chlorination product are all entering commercialization this year, while semiconductor samples passed customer specs and a second opportunity was awarded.
- FY26 guidance held at 25% revenue growth, 20% margin: Q-on-Q expansion expected, with H2 acceleration backed by orders already on hand.
- What to watch next quarter: Whether SDA pricing has truly bottomed, the pace of electrolyte customer ramp once automated lines come online in September, and any update on the Stage 2 supplier delay holding back pharma intermediate validations.
Demand & Volume Recovery
- Export markets driving the rebound: U.S. and Europe demand has picked up while Chinese demand remains nearly negligible; the export share shifted from 61% to 71%, reflecting both stronger overseas pull and a deliberate move away from price-competitive domestic sales.
- Capacity now tight: Until May, plants were not fully occupied; now most capacities are filled and the company has started becoming selective about what it manufactures.
- Second-half visibility is concrete: Management expressed "100% confidence" in H2 acceleration because orders are already on hand, with clear line of sight at least through December.
- SDA volume growth commitment intact: The company is sticking to 40–70% volume growth, give or take a quarter, driven by Euro 6 demand today and Euro 7 orders beginning from October.
Chintan Shah: "100% confidence because we have orders on hand most of the things. So, there is not if and but. At least till December, we have very clear visibility of what we are getting into."
SDA: Volume Strength, Value Erosion
- Pricing stuck at last year's levels: Raw material costs have fallen sharply, and SDA pricing has followed them down; management sees no significant change on the raw material front and believes the price has now bottomed out.
- Volume commitments will be met, value will not: The company is "absolutely sure" of hitting volume targets but explicitly acknowledged it will fall short on the value side because of the price erosion.
- Euro 7 catalyst ahead: Orders for Euro 7 supplies begin from October 2025, with full implementation in 2027; the company is also validating another Euro 7 product for a large customer.
- Demand structurally supported: SDA products address large diesel vehicles where EV penetration is not happening; management cited California's slow electrification, expected U.S. withdrawal of EV incentives, Germany's missing EV push, and a shift toward hybrids as factors extending the IC engine runway, with car-segment IC engines potentially surviving 20 more years.
Chintan Shah: "In terms of volumes what we have committed, we are absolutely sure to meet those volume commitments. Unfortunately, not the value commitments."
New Product Commercialization Pipeline
- PASC segment poised for a breakout year: Two large agro intermediates are now being consistently manufactured at plant scale for Q3 order execution; a second agro intermediate received commercial approval with orders for H2 supply; a high-potential domestic agro intermediate gained traction with one major customer approval and samples heading to another large customer this quarter.
- Photo-chlorination agrochemicals entering production: Fully approved by the customer, with production starting in August and commercialization-mode supplies beginning from November; orders for November and December are already placed.
- Electrolyte salts gaining commercial traction: A second approved product is now being manufactured at plant level with dispatch expected within the current quarter; a separate customer manufacturing hybrid-vehicle batteries approved material and placed a first small-scale commercial order for extended validations.
- Pharma intermediates progressing, with a delay: Plant-scale validation batches for the third pharma intermediate were successfully delivered; the fourth is still in pilot scale. The delay traces to a Stage 2 supplier whose own capex delays are holding up overall material validation. Management expects commercialization around August or September 2026.
- Semiconductor milestone achieved: Pilot-scale samples met customer specifications, a first for the company; the customer asked for two repeat pilot runs to demonstrate consistency and awarded work on a second opportunity. Slow commercialization is expected to begin in 2027, leading to full-scale commercialization by 2029.
Chintan Shah: "This is the first time. That's why I said in my speech that the significant development and achievement for us is to deliver a sample which meets with the customer specification."
Margins: The Recovery Path
- Q1 margin jump explained: EBITDA margin expanded 287 bps YoY to 14.8%, driven by a 4.1% decrease in COGS, partly offset by a 1.2% rise in other expenses. The mix shift toward higher exports and SDA, plus a purposeful slowdown in lower-margin Phase Transfer Catalyst sales (because that material was consumed internally for SDA production), all contributed.
- Sequential expansion promised: Management expects Q-on-Q margin improvement through the year, with clear visibility at least until December, and is sticking to the 20% full-year margin forecast.
- R&D costs are the price of the pipeline: The semiconductor and niche-product pipeline is not an overnight development; the company has been working on it for 7–8 years, with every learning requiring new installations, trials, and analytics, all of which carried costs that were absorbed along the way.
Chintan Shah: "Why do you want to push our cost high unnecessary? No, no. jokes apart. This is not an overnight development. It's probably we have been working on this since probably 7 years, at least, maybe 8 years, if I may not be wrong."
Electrolyte & Energy Storage: The Next Leg
- Revenue scale taking shape: Management estimates the existing facility can generate close to ₹100 crores in electrolyte revenue, with the segment contributing roughly 10% of the total top line over the next financial years; current-quarter revenue is expected between ₹15–20 crores.
- Margins comparable to SDA: Electrolyte margins are described as "as good as" the SDA segment, though no specific EBITDA margin figure was provided when pressed.
- Near-term ramp gated by customer automation: The customer's automated systems are currently operating at only 30% efficiency, with manual workarounds feeding just 30% of the required material; the customer expects to have eight automated systems in place by September or October, at which point a significant volume rise is expected.
- Further expansion will need Jolva: Once the existing facility reaches its limits, additional capacity will require investment at the upcoming greenfield site.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 25% revenue growth for FY26 | FY26 full year |
| EBITDA margin | 20% margin, with Q-on-Q expansion through the year | FY26 full year; visibility at least until December |
| SDA volume growth | 40–70% volume/value growth, give or take a quarter | FY26, with Euro 7 orders beginning October 2025 |
| PASC commercialization | Two large agro intermediates executing orders; one small production block commercializing | Q3 FY26 for large orders; January 2026 for small block |
| Photo-chlorination supplies | Production from August, commercialization supplies from November | November–December 2025 orders placed |
| Electrolyte dispatch | Second approved product dispatched from plant | Within current quarter (Q1 FY26) |
| Pharma intermediate commercialization | First products expected to begin commercializing | August–September 2026 |
| Semiconductor commercialization | Slow commercialization begins, leading to full-scale | 2027 start; full-scale by 2029 |
| Next financial year growth | "Probably another 20% to 25% growth" | FY27 |
| Next financial year margin | "About similar, 20% level" | FY27 |
| Capex | About ₹110 crores | FY26 |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Operating revenue | ₹116.9 cr, +11% YoY and +8% QoQ |
| EBITDA | ₹17.3 cr, +37% YoY and +94% QoQ |
| EBITDA margin | 14.8%, +287 bps YoY; COGS down 4.1% partly offset by other expenses up 1.2% |
| PBT | ₹9.1 cr vs ₹6.8 cr in Q1 FY25 |
| PAT | ₹6.6 cr vs ₹5.2 cr in Q1 FY25 |
| PAT margin | 5.7% vs 4.9% in Q1 FY25 |
| EPS | ₹2.84 vs ₹2.23 in Q1 FY25 |
| Exports | ₹83 cr, 71% of revenue vs 61% last quarter |
| Phase Transfer Catalyst revenue | ₹32.3 cr, +9% YoY and -17% QoQ |
| Structure Directing Agents revenue | ₹39.4 cr, +13% YoY and +14% QoQ |
| PASC and Electrolyte Salts revenue | ₹43.2 cr, +11% YoY and +32% QoQ |
| FY26 revenue growth guidance | 25% |
| FY26 EBITDA margin guidance | 20% |
| FY26 capex plan | ₹110 cr |
| Electrolyte Salts FY26 revenue guidance | ₹15–20 cr |